BMS-986259
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Decompensated Heart Failure
Conditions
Acute Decompensated Heart Failure
Trial Timeline
Nov 6, 2020 → Jul 19, 2021
NCT ID
NCT04318093About BMS-986259
BMS-986259 is a phase 2 stage product being developed by Bristol Myers Squibb for Acute Decompensated Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT04318093. Target conditions include Acute Decompensated Heart Failure.
What happened to similar drugs?
20 of 20 similar drugs in Acute Decompensated Heart Failure were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04318093 | Phase 2 | Completed |
| NCT04237831 | Phase 1 | Completed |
| NCT04008992 | Phase 1 | Completed |
Competing Products
20 competing products in Acute Decompensated Heart Failure